Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles

Li, Aixue; Zhao, Yunan; Li, Yixiu; Jiang, Liangdi; Gu, Yongwei; Liu, Jiyong

doi:10.1080/10717544.2021.1938757

Cited by 68 publications

(30 citation statements)

References 167 publications

(151 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To make that empirical, it is necessary to extract cell membrane, prepare the core and shell-core which need some steps to be taken including isolation of cell membrane thereafter fusion to core NPs. These cells membranes properties make bionics useful to escape from immune surveillance as well as targeted and deep penetration into target cells [ 125 ]. Bionic can also be served as a vector for drug delivery and controlled release.…”

Section: Advanced Strategies For Crc Drug Deliverymentioning

confidence: 99%

Recent advances in targeted drug delivery systems for resistant colorectal cancer

et al. 2022

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the deadliest cancers in the world, the incidences and morality rate are rising and poses an important threat to the public health. It is known that multiple drug resistance (MDR) is one of the major obstacles in CRC treatment. Tumor microenvironment plus genomic instability, tumor derived exosomes (TDE), cancer stem cells (CSCs), circulating tumor cells (CTCs), cell-free DNA (cfDNA), as well as cellular signaling pathways are important issues regarding resistance. Since non-targeted therapy causes toxicity, diverse side effects, and undesired efficacy, targeted therapy with contribution of various carriers has been developed to address the mentioned shortcomings. In this paper the underlying causes of MDR and then various targeting strategies including exosomes, liposomes, hydrogels, cell-based carriers and theranostics which are utilized to overcome therapeutic resistance will be described. We also discuss implication of emerging approaches involving single cell approaches and computer-aided drug delivery with high potential for meeting CRC medical needs.

show abstract

Section: Advanced Strategies For Crc Drug Deliverymentioning

confidence: 99%

Recent advances in targeted drug delivery systems for resistant colorectal cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In summary, using macrophage membranes or macrophage-derived EVs as carriers can improve drug loading and partially solve the shortage of cell sources. These novel drug carriers can not only target tumor sites but also activate antitumor immune responses and therefore hold great promise in cancer therapy (173)(174)(175).…”

Section: Macrophage Membrane-coated Nps (Mmc-nps) and Macrophage Extracellular Vesicle-coated Nps (Mevc-nps)mentioning

confidence: 99%

Engineering Macrophages via Nanotechnology and Genetic Manipulation for Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

Macrophages play critical roles in tumor progression. In the tumor microenvironment, macrophages display highly diverse phenotypes and may perform antitumorigenic or protumorigenic functions in a context-dependent manner. Recent studies have shown that macrophages can be engineered to transport drug nanoparticles (NPs) to tumor sites in a targeted manner, thereby exerting significant anticancer effects. In addition, macrophages engineered to express chimeric antigen receptors (CARs) were shown to actively migrate to tumor sites and eliminate tumor cells through phagocytosis. Importantly, after reaching tumor sites, these engineered macrophages can significantly change the otherwise immune-suppressive tumor microenvironment and thereby enhance T cell-mediated anticancer immune responses. In this review, we first introduce the multifaceted activities of macrophages and the principles of nanotechnology in cancer therapy and then elaborate on macrophage engineering via nanotechnology or genetic approaches and discuss the effects, mechanisms, and limitations of such engineered macrophages, with a focus on using live macrophages as carriers to actively deliver NP drugs to tumor sites. Several new directions in macrophage engineering are reviewed, such as transporting NP drugs through macrophage cell membranes or extracellular vesicles, reprogramming tumor-associated macrophages (TAMs) by nanotechnology, and engineering macrophages with CARs. Finally, we discuss the possibility of combining engineered macrophages and other treatments to improve outcomes in cancer therapy.

show abstract

“…This achievement represents a remarkable advancement in pharmaceutical science. In recent years, various nanosystems targeting the drug delivery of different anticancer drugs were proposed and based on biomimetic approaches [37].…”

Section: The Last Decade-an Age Of Great Promisementioning

confidence: 99%

Bioinspired NEMS—Prospective of Collaboration with Nature

et al. 2022

View full text Add to dashboard Cite

show abstract

Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles

Cited by 68 publications

References 167 publications

Recent advances in targeted drug delivery systems for resistant colorectal cancer

Recent advances in targeted drug delivery systems for resistant colorectal cancer

Engineering Macrophages via Nanotechnology and Genetic Manipulation for Cancer Therapy

Bioinspired NEMS—Prospective of Collaboration with Nature

Contact Info

Product

Resources

About